---
title: "Publications"
layout: page
---

**Patient-reported outcomes (PROs):** 

SPIRIT-PRO extension (PRO-specific protocol guidance): https://pubmed.ncbi.nlm.nih.gov/29411037/
SISAQOL recommendations (statistical standards for PRO data in randomized trials):  https://pubmed.ncbi.nlm.nih.gov/32007209/
CONSORT-PRO extension: https://pubmed.ncbi.nlm.nih.gov/23443445/
PRO-cision Medicine Toolkit (Medical Care edition focused on PROs implemented in clinical practice):
https://pubmed.ncbi.nlm.nih.gov/30985589/
https://pubmed.ncbi.nlm.nih.gov/30985590/
https://pubmed.ncbi.nlm.nih.gov/30985591/
https://pubmed.ncbi.nlm.nih.gov/30985592/
https://pubmed.ncbi.nlm.nih.gov/30985593/
https://pubmed.ncbi.nlm.nih.gov/30985594/
https://pubmed.ncbi.nlm.nih.gov/30985595/
https://pubmed.ncbi.nlm.nih.gov/30985596/
https://pubmed.ncbi.nlm.nih.gov/30985597/
https://pubmed.ncbi.nlm.nih.gov/30985598/
https://pubmed.ncbi.nlm.nih.gov/30985599/
https://pubmed.ncbi.nlm.nih.gov/30985600/
https://pubmed.ncbi.nlm.nih.gov/30985601/
https://pubmed.ncbi.nlm.nih.gov/30985602/

**PROMIS:**
PROMIS scales to PRO-CTCAE and single-item numeric rating scale items:  https://pubmed.ncbi.nlm.nih.gov/33305344/
PROMIS reporting recommendations:  https://pubmed.ncbi.nlm.nih.gov/32215788/

**PRO-CTCAE:**
Item generation: https://pubmed.ncbi.nlm.nih.gov/25265940/
Cognitive testing: https://pubmed.ncbi.nlm.nih.gov/23868457/
Validity, reliability, & responsiveness: https://pubmed.ncbi.nlm.nih.gov/26270597/
Comparison of modes of administration (paper, web, & automated telephone):  https://pubmed.ncbi.nlm.nih.gov/26892667/ (also note that this publication provides data on amount of time needed for patients to complete PRO-CTCAE items – about 10 seconds per item by paper or web, and 15 seconds per item by automated telephone [see Table 4])
Assessment of patient recall from 1 to 4 weeks: https://pubmed.ncbi.nlm.nih.gov/28545337/
Pediatric (and proxy) PRO-CTCAE: https://pubmed.ncbi.nlm.nih.gov/28062347/
US FDA & NCI view on clinical review, IND safety reporting, & site inspections:  https://pubmed.ncbi.nlm.nih.gov/29237718/
Strategy to select symptomatic AEs for administration:  https://pubmed.ncbi.nlm.nih.gov/30230365/
What do “Mild”, “Moderate”, … mean to patients?:  https://pubmed.ncbi.nlm.nih.gov/29129739/
Use of free text items: https://pubmed.ncbi.nlm.nih.gov/30840079/
Feasibility of PRO-CTCAE reporting:  https://pubmed.ncbi.nlm.nih.gov/28463161/;  https://pubmed.ncbi.nlm.nih.gov/30204536/
Composite scoring algorithm: https://pubmed.ncbi.nlm.nih.gov/33258687/
Example of PRO-CTCAE in a trial (PRO-CTCAE is reported in the supplemental appendix):  https://pubmed.ncbi.nlm.nih.gov/30575484/
PRO-CTCAE baseline adjustment method: https://pubmed.ncbi.nlm.nih.gov/31556911/

**Adverse event (AE) analysis:**
Lancet Haematology Commission on modernizing approach to AEs: https://pubmed.ncbi.nlm.nih.gov/29907552/
Update to Lancet Haematology Commission: https://pubmed.ncbi.nlm.nih.gov/35483398/
Thanarajasingam ToxT references:
https://pubmed.ncbi.nlm.nih.gov/27083333/
https://pubmed.ncbi.nlm.nih.gov/27396640/
https://pubmed.ncbi.nlm.nih.gov/32470440/
https://pubmed.ncbi.nlm.nih.gov/32951293/

**Rare diseases:**
https://pubmed.ncbi.nlm.nih.gov/26868354/
https://pubmed.ncbi.nlm.nih.gov/26868355/
https://pubmed.ncbi.nlm.nih.gov/26868356/

![image](https://github.com/DueckLab/DueckLab.github.io/assets/141273935/cabd255e-aa02-4d1a-928e-ebfdc46ceb8f)
